The STK32C Monoclonal Antibody (PACO12534) is a valuable tool for studying the STK32C protein, which is involved in cellular processes related to cell proliferation and differentiation. This antibody, derived from mouse hybridoma cells, is highly specific to human STK32C and has been validated for use in immunofluorescence and immunohistochemistry applications.STK32C, a serine/threonine protein kinase, is known to play a role in signaling pathways that regulate cell cycle progression and cell survival. Its dysregulation has been implicated in various diseases, including cancer and neurological disorders.
By targeting STK32C with this monoclonal antibody, researchers can gain insight into its function and potential therapeutic implications in these disease contexts.The STK32C Monoclonal Antibody (PACO12534) is a valuable tool for investigating the role of STK32C in cellular processes and disease pathogenesis. Its specificity and versatility make it a reliable choice for studies in molecular biology, cancer research, and drug discovery efforts aimed at targeting STK32C for therapeutic purposes.
YANK3: is a member of the serine/threonine protein kinase family. The specific function of this kinase is not known. [provided by RefSeq, Jul 2008]Protein type: Protein kinase, AGC; Kinase, protein; Protein kinase, Ser/Thr (non-receptor); EC 2.7.11.1; AGC group; YANK familyChromosomal Location of Human Ortholog: 10q26.3Cellular Component: intracellularMolecular Function: ATP binding; metal ion binding; protein serine/threonine kinase activityBiological Process: peptidyl-serine phosphorylation
UniProt Protein Details:
NCBI Summary:
The protein encoded by this gene is a member of the serine/threonine protein kinase family. It is thought that this family member is functional in brain due to its high expression levels there. DNA methylation differences have been found in this gene in monozygotic twins that are discordant for adolescent depression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]
